

高橋 雅英

名古屋大学大学院医学系研究科長・医学部長 分子病理学／腫瘍病理学 教授

1979年名古屋大学医学部卒業、1983年名古屋大学大学院医学系研究科修了。同年、渡米しハーバード大学医学部、Dana-Farber 癌研究所リサーチフェローとしてRET癌遺伝子を発見、研究を行う。1985年には愛知県がんセンター研究所研究員、1990年からは名古屋大学に戻り、医学部病理学第2講座助手、助教授を経て1996年に教授就任。2003年名古屋大学大学院医学系研究科附属神経疾患・腫瘍分子医学研究センター・センター長（分子病理学分野教授）、2012年4月から名古屋大学大学院医学系研究科長・医学部長。

<専門・研究対象>

実験病理学

<受賞歴>

2010年	5月中日文化
2006年	3月読売東海医学賞
2001年	4月日本病理学
1993年	日本病理学会学術研究
1990年	日本癌学会奨励賞

<主な研究実績>

1. Miyake H, Maeda K, Asai N, Shibata R, Ichimiya H, Isotani-Sakakibara M, Yamamura Y, Kato K, Enomoto A, Takahashi M, Murohara T: The actin-binding protein Girdin and its Akt-mediated phosphorylation regulate neointima formation after vascular injury. *Circ Res*, in press (2011)
2. Saito S, Murakumo Y, Tsuzuki T, Dambara A, Kato T, Enomoto A, Asai N, Maruyama S, Matsuo S, Takahashi M: Analysis of GDNF-inducible zinc finger protein 1 expression in human diseased kidney. *Human Pathol*, in press (2011)
3. Nakamura N, Naruse K, Kobayashi Y, Matsuki T, Hamada Y, Nakashima E, Kamiya H, Hata M, Nishikawa T, Enomoto A, Takahashi M, Murohara T, Matsubara T, Nakamura J: High glucose impairs the proliferation and increases the apoptosis of endothelial progenitor cell by suppression of Akt. *J Diabet Invest*, in press (2011)
4. Matsushita E, Asai N, Enomoto A, Kawamoto Y, Kato T, Mii S., Maeda K, Shibata R, Hattori S, Hagikura M, Takahashi K, Sokabe M, Murakumo Y, Murohara T, Takahashi M: Protective role of Gipie, a Girdin family protein, in endoplasmic reticulum stress responses in endothelial cell. *Mol Biol Cell*, 22, 736-747 (2011)

5. Miyamoto R, Jijiwa M, Asai M, Kawai K, Ishida-Takagishi M, Mii S, Asai N, Enomoto A, Murakumo Y, Yoshimura A, Takahashi M: Loss of Sprouty2 partially rescues renal hypoplasia and stomach hypoganglionosis but not intestinal aganglionosis in Ret Y1062F mutant mice. *Dev Biol*, 349, 160-168 (2011)
6. Hagikura M, Murakumo Y, Hasegawa M, Jijiwa M, Hagiwara S, Mii S, Hagikura S, Matsukawa Y, Yoshino Y, Hattori R, Wakai K, Nakamura S, Gotoh M, Takahashi M: Correlation of pathological grade and tumor stage of urothelial carcinoma with CD109 expression. *Pathol Int*, 60, 735-743 (2010)
7. Ohgami N, Ida-Eto M, Shimotake T, Sakashita N, Sone M, Nakashima T, Tabuchi K, Hoshino T, Shimada A, Tsuzuki T, Yamamoto M, Sobue G, Jijiwa M, Asai N, Hara A, Takahashi M, Kato M: c-Ret-mediated hearing loss in mice with Hirschsprung disease. *Proc Natl Acad Sci USA*, 107, 13051-13056 (2010)
8. Yamaguchi M, Suyari O, Nagai R, Takahashi M: dGirdin a new player of Akt /PKB signaling in *Drosophila Melanogaster*. *Front Biosci*, 15, 1164-1171 (2010)
9. Weng L, Enomoto A, Ishida-Takagishi M, Asai N, Takahashi M: Girding for migratory cues: Role of the Akt substrate Girdin in cancer progression and angiogenesis. *Cancer Sci*, 101, 836-842 (2010)
10. Kurotsuchi A, Murakumo Y, Jijiwa M, Kurokawa K, Itoh Y, Kodama Y, Kato T, Enomoto A, Asai N, Terasaki H, Takahashi M: Analysis of DOK-6 function in downstream signaling of RET in human neuroblastoma cells. *Cancer Sci*, 101, 1147-1155 (2010)
11. Kato M, Takeda K, Hossain K, Thang ND, Kaneko Y, Kumasaka M, Yamanoshita O, Uemura N, Takahashi M, Ohgami N, Kawamoto Y: A redox-linked novel pathway for arsenic-mediated RET tyrosine kinase activation. *J Cell Biochem*, 110, 399-407 (2010)
12. Hagiwara S, Murakumo Y, Mii S, Shigetomi T, Yamamoto N, Furue H, Ueda M, Takahashi M: Processing of CD109 by furin and its role in the regulation of TGF-beta signaling. *Oncogene*, 29, 2181-2191 (2010)
13. Ohshima Y, Yajima I, Kumasaka MY, Yanagishita T, Watanabe D, Takahashi M, Inoue Y, Ihn H, Matsumoto Y, Kato M: CD109 expression levels in malignant melanoma. *J Dermatol Sci*, 57, 140-142 (2010)
14. Kumasaka MY, Yajima I, Hossain K, Iida M, Tsuzuki T, Ohno T, Takahashi M, Yanagisawa M, Kato M: A novel mouse model for de novo Melanoma. *Cancer Res*, 70, 24-29 (2010)
15. Hagiwara S et al., Processing of CD109 by furin and its role in the regulation of TGF-beta signaling. *Oncogene*, in press (2010)
16. Enomoto A et al., Roles of Disrupted-in-Schizophrenia 1-interacting protein Girdin

in postnatal development of the dentate gyrus. *Neuron*, 63, 774-787 (2009)

17. Lu B et al., *Etv4* and *Etv5* are required downstream of GDNF and Ret for kidney branching morphogenesis. *Nature Genet*, 41, 1295-1302 (2009)

18. Kitamura T et al. Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. *Nature Cell Biol*, 10, 329-337 (2008)

19. Jiang P et al. An actin-binding protein Girdin regulates the motility of breast cancer cells. *Cancer Res*, 68, 1310-1318 (2008)

20. Asai N et al. Targeted mutation of serine 697 in the Ret tyrosine kinase causes migration defect of enteric neural crest cells. *Development*, 133, 4507-4516 (2006)

21. Uchida M et al. Dok-4 regulates GDNF-dependent neurite outgrowth through downstream activation of Rap1 and mitogen-activated protein kinase. *J Cell Sci*, 119, 3067-3077 (2006)

22. Enomoto A et al. Akt/PKB regulates actin organization and cell motility via Girdin/APE. *Dev Cell*, 9, 389-402 (2005)

23. Morinaga T et al. GDNF-inducible zinc finger protein 1 is a sequence-specific transcriptional repressor that binds to the HOXA10 gene regulatory region. *Nucleic Acids Res*, 33, 4191-4201 (2005)

24. Jijiwa M et al. A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia. *Mol Cell Biol*, 24, 8026-8036 (2004)

25. Hashimoto M et al. Expression of CD109 in human cancer. *Oncogene*, 23, 3716-3720 (2004)

26. Fukuda T et al. Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase. *J Biol Chem*, 277, 19114-19121 (2002)

27. Iwashita T et al. Functional analysis of RET with Hirschsprung's mutations affecting its kinase domain. *Gastroenterology*, 121, 24-33 (2001)

28. Takahashi M et al. The GDNF/RET signaling pathway and human diseases. *Cytokine & Growth Factor Reviews*, 12, 361-373 (2001)

29. Kawai K et al. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation. *Cancer Res*, 60, 5254-5260 (2000)

30. Ito S et al. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary carcinoma, and Hirschsprung's disease phenotype. *Cancer Res*, 57, 2870-2872 (1997)

31. Klein RD et al. A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor. *Nature*, 387, 717-721 (1997)

32. Treanor JJS et al. Characterization of a multicomponent receptor for GDNF. *Nature*,

382, 80-83 (1996)

33. Asai N et al. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. *Mol Cell Biol*, 15, 1613-1619 (1995)

34. Iwamoto T et al. Aberrant melanogenesis and melanocytic tumor development in transgenic mice that carry a metallothionein/ret fusion gene. *EMBO J*, 10, 3167-3175 (1991)

35. Takahashi M et al. Activation of a novel human transforming gene, ret, by DNA rearrangement. *Cell*, 42, 581-588 (1985)